TherapeuticsMD (NASDAQ:TXMD) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a report issued on Friday morning. The firm issued a hold rating on the stock.

TherapeuticsMD Stock Performance

Shares of TXMD stock opened at $1.09 on Friday. TherapeuticsMD has a fifty-two week low of $1.05 and a fifty-two week high of $2.75. The stock has a 50 day simple moving average of $1.37 and a two-hundred day simple moving average of $1.61.

Institutional Inflows and Outflows

An institutional investor recently raised its position in TherapeuticsMD stock. Clearline Capital LP grew its stake in shares of TherapeuticsMD, Inc. (NASDAQ:TXMD) by 18.9% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 636,622 shares of the company’s stock after acquiring an additional 101,282 shares during the period. Clearline Capital LP owned 5.52% of TherapeuticsMD worth $1,025,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 30.74% of the company’s stock.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.